HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The full press release is available at https://ibn.fm/CTxXi.
HeartBeam is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement.
This reorganization reflects HeartBeam’s commitment to rapid commercialization and global expansion. By placing key executives in charge of focused teams, the company aims to accelerate product development and market penetration. The move also signals a shift toward capital efficiency, which is critical for a growth-stage medical technology firm. The implications of this announcement are significant for investors and the healthcare industry. With a strong patent portfolio and recent FDA clearances, HeartBeam is well-positioned to capture market share in the cardiac monitoring space. The company’s focus on heart attack detection, in addition to arrhythmia assessment, addresses a major unmet medical need. Expanding partnerships with governments and health systems could drive widespread adoption of its technology, potentially reducing healthcare costs and improving patient outcomes.
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. Forward-looking statements in this article involve risks and uncertainties as detailed in the company's SEC filings. This reorganization positions HeartBeam to execute on its vision of redefining cardiac health management through innovative 3D ECG technology.
